Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9-nitrocamptothecin in hormone refractory prostate cancer
NCT00005820Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 2000
- Primary completion
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rubitecan in prostate cancer (PCa), sponsored by Cancer and Leukemia Group B. Primary endpoint: Time to disease and PSA progression up to 2 years. Started May 2000; status: completed.
02
Drugs
rubitecan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00005820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005820.